• In June 2026, Oruka Therapeutics, Inc. amended its IL-23 License Agreement with Paragon Therapeutics, expanding ORKA-001’s permitted uses to all therapeutic, prophylactic, palliative, and diagnostic applications, while imposing staged restrictions on clinical trial dosing for inflammatory bowel disease through 2030.
• This broadened field, combined with conditional relaxation of certain limits following any material transaction or change of control, materially increases Oruka’s optionality in how it develops and positions its IL-23 program.
• We will now examine how the broadened IL-23 development field shapes Oruka’s investment narrative and future optionality for ORKA-001.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Oruka Therapeutics' Investment Narrative?

To own Oruka Therapeutics today, you have to believe that its IL‑23 and IL‑17 antibody platforms can eventually justify a rich valuation despite zero revenue, persistent losses and recent dilution. The new IL‑23 license amendment fits that thesis by quietly expanding what ORKA‑001 can be used for, giving management more room to explore psoriasis, potentially adjacent indications and even diagnostic angles, while accepting a slower path in inflammatory bowel disease because of the dosing restrictions. In the near term, the key catalysts still sit with readouts from EVERLAST‑A longer‑term data and progress across ORKA‑002 and ORCA‑SURGE, rather than this contract tweak itself. The bigger immediate swing factors remain cash burn, follow‑on supply from the recent offering and how the stock behaves once lock‑ups expire.

However, one risk around future capital needs and shareholder dilution is easy to overlook. Our valuation report unveils the possibility Oruka Therapeutics' shares may be trading at a premium.

Exploring Other Perspectives

Investors in the Simply Wall St Community put Oruka’s fair value anywhere between US$14.22 and US$142.17 across 2 views, underlining how differently people read the same science and cash burn profile, especially with ORKA‑001’s broadened field and longer pathway in inflammatory bowel disease now in play.

Explore 2 other fair value estimates on Oruka Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Oruka Therapeutics research is our analysis highlighting 5 important warning signs that could impact your investment decision.
• Our free Oruka Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oruka Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.